Psychedelic Medicine Sector

[gfp927z]

>>> Seelos Therapeutics Announces its Inclusion in the First U.S. Listed Exchange Traded Fund (ETF) Focused on Psychedelics


Yahoo Finance

June 1, 2021


https://finance.yahoo.com/news/seelos-therapeutics-announces-inclusion-first-120000043.html


- ETF Trades on the New York Stock Exchange Under the Symbol PSY


NEW YORK, June 1, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has been included in the Defiance Next Gen Altered Experience ETF, the first U.S. listed Exchange Traded Fund (ETF) focused on psychedelics which began trading on Friday, May 28th on the New York Stock Exchange under the symbol PSY.

Seelos' inclusion is based on its lead program SLS-002 (intranasal racemic ketamine), which recently released positive top-line data from Part 1, the open-label cohort, of its potentially registrational Proof-of-Concept study for Acute Suicidal Ideation and Behavior (ASIB) in patients with Major Depressive Disorder (MDD).

The Defiance Next Gen Altered Experience ETF, managed by Defiance ETFs, LLC, is the first U.S. listed psychedelic ETF which seeks to track the BITA Medical Psychedelics, Cannabis, and Ketamine Index, a rules-based index that tracks the performance of companies, listed in North American Exchanges, that operate business models focused on the usage of Psychedelics, Medical Cannabis, and Ketamine for medicinal and health treatment purposes. Companies included in the ETF must have a minimum market capitalization of $75 million, and operate in the production of, distribution of, or services related to medical psychedelics, medical cannabis or ketamine and its derivatives.

If you or a loved one are having thoughts of suicide, please seek immediate medical help, go to your nearest emergency room, or call the National Suicide Prevention Lifeline at 1-800-273-8255.

About Defiance ETFs

Founded in 2018, Defiance ETFs, LLC is a FinTech asset manager and an exchange-traded funds (ETFs) sponsor focused on the next generation of investors. The Psychedelic ETF ($PSY) joins Defiance's suite of first-mover disruptive ETFs, which includes Next Gen H2 ($HDRO), the first SPAC ETF ($SPAK), and the first 5G ETF ($FIVG).

About SLS-002

SLS-002 is intranasal racemic ketamine with investigational new drug applications for the treatment of ASIB in MDD or Post-Traumatic Stress Disorder (PTSD). SLS-002 was originally derived from a Javelin Pharmaceuticals, Inc./Hospira, Inc. program with 16 clinical studies involving approximately 500 subjects. SLS-002 is being developed to address an unmet need for a therapy to treat suicidality in the U.S. Traditionally, anti-depressants have been used in this setting, but many of the existing treatments are known to contribute to an increased risk of suicidal thoughts in some circumstances, and if they are effective, it often takes weeks for the full therapeutic effect to be manifested. Based on information gathered from the databases of the Agency for Healthcare Research and Quality, there were more than 1,000,000 visits to emergency rooms for suicide attempts in 2013 in the U.S. alone. Experimental studies suggest ketamine has the potential to be a rapid, effective treatment for depression and suicidality.

<<<